Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.45 | N/A | +3.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.45 | N/A | +3.21% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the impact of external factors on performance. They remain focused on long-term growth strategies.
Management highlighted ongoing challenges in the supply chain.
They emphasized a commitment to innovation despite market pressures.
Boston Scientific's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock dropped 4.74%, likely reflecting investor concerns about ongoing supply chain challenges and the lack of revenue data. The absence of guidance may also have contributed to the negative market reaction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OTIS WORLDWIDE CORP
Jan 31, 2022